Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cue Biopharma (CUE) Profit After Tax (2018 - 2025)

Historic Profit After Tax for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to -$7.4 million.

  • Cue Biopharma's Profit After Tax rose 1399.54% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.7 million, marking a year-over-year increase of 1553.17%. This contributed to the annual value of -$40.7 million for FY2024, which is 1982.73% up from last year.
  • Latest data reveals that Cue Biopharma reported Profit After Tax of -$7.4 million as of Q3 2025, which was up 1399.54% from -$8.5 million recorded in Q2 2025.
  • Cue Biopharma's Profit After Tax's 5-year high stood at -$7.4 million during Q3 2025, with a 5-year trough of -$14.6 million in Q4 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$12.3 million (2025), whereas its average is -$11.4 million.
  • In the last 5 years, Cue Biopharma's Profit After Tax tumbled by 7404.22% in 2022 and then skyrocketed by 2931.37% in 2024.
  • Over the past 5 years, Cue Biopharma's Profit After Tax (Quarter) stood at -$8.4 million in 2021, then crashed by 74.04% to -$14.6 million in 2022, then grew by 7.94% to -$13.4 million in 2023, then grew by 29.31% to -$9.5 million in 2024, then increased by 21.57% to -$7.4 million in 2025.
  • Its Profit After Tax stands at -$7.4 million for Q3 2025, versus -$8.5 million for Q2 2025 and -$12.3 million for Q1 2025.